Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord mesenchymal stem cell injection for hepatitis B virus-related acute-on-chronic liver failure
CTR20250672Phase 3Active
- Sponsor
- Tianjin Angsai Cell Gene Engineering Co., Ltd.
- Start
- Apr 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of human umbilical cord mesenchymal stem cells in acute-on-chronic liver failure (ACLF), sponsored by Tianjin Angsai Cell Gene Engineering Co., Ltd.. Started Apr 2025; status: active.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on CTR20250672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250672.